SER
Price
$8.93
Change
+$0.44 (+5.18%)
Updated
May 15, 9:36 AM EST
XTLB
Price
$2.65
Change
-$0.02 (-0.75%)
Updated
May 15, 9:22 AM EST
19 days until earnings call
Ad is loading...

SER vs XTLB

Header iconSER vs XTLB Comparison
Open Charts SER vs XTLBBanner chart's image
Serina Therapeutics
Price$8.93
Change+$0.44 (+5.18%)
Volume$500
CapitalizationN/A
XTL Biopharmaceuticals
Price$2.65
Change-$0.02 (-0.75%)
Volume$193
CapitalizationN/A
View a ticker or compare two or three
SER vs XTLB Comparison Chart

Loading...

VS
SER vs. XTLB commentary
May 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SER is a Hold and XTLB is a Hold.

COMPARISON
Comparison
May 15, 2024
Stock price -- (SER: $9.23 vs. XTLB: $2.57)
Brand notoriety: SER and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SER: 48% vs. XTLB: 2%
Market capitalization -- SER: $23.09M vs. XTLB: $14.76M
SER [@Biotechnology] is valued at $23.09M. XTLB’s [@Biotechnology] market capitalization is $14.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $585.17B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SER’s FA Score shows that 0 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).

  • SER’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, SER is a better buy in the long-term than XTLB.

Price Growth

SER (@Biotechnology) experienced а -1.65% price change this week, while XTLB (@Biotechnology) price change was +0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.30%. For the same industry, the average monthly price growth was +0.43%, and the average quarterly price growth was +61.17%.

Reported Earning Dates

SER is expected to report earnings on Mar 31, 2023.

XTLB is expected to report earnings on Jul 23, 2024.

Industries' Descriptions

@Biotechnology (+0.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for SER with price predictions.
OPEN
A.I.dvisor published
a Summary for XTLB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SER($23.1M) has a higher market cap than XTLB($14.8M). SER YTD gains are higher at: 2298.701 vs. XTLB (154.430).
SERXTLBSER / XTLB
Capitalization23.1M14.8M156%
EBITDAN/AN/A-
Gain YTD2298.701154.4301,489%
P/E Ratio19.34N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
XTLB: Fundamental Ratings
XTLB
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
88
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSCCX14.810.14
+0.95%
JPMorgan Small Cap Blend C
MRVNX12.710.07
+0.55%
Mirova International Sustainable Eq N
FLACX72.960.37
+0.51%
Fidelity Advisor Stock Sel All Cp C
EQNRX21.630.11
+0.51%
MFS Equity Income R1
GSTIX11.83N/A
N/A
Goldman Sachs Strategic Growth Instl

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been loosely correlated with GERN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SER jumps, then GERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
+11.13%
GERN - SER
65%
Loosely correlated
-1.60%
FUSN - SER
64%
Loosely correlated
N/A
XTLB - SER
59%
Loosely correlated
-11.99%
ELVN - SER
37%
Loosely correlated
-2.53%
TOVX - SER
34%
Loosely correlated
-0.03%
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
-11.99%
SER - XTLB
59%
Loosely correlated
+11.13%
ADTX - XTLB
27%
Poorly correlated
+6.80%
TOVX - XTLB
26%
Poorly correlated
-0.03%
BCRX - XTLB
25%
Poorly correlated
-4.80%
CRNX - XTLB
25%
Poorly correlated
+3.03%
More